Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 43

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 43
---
. 1 to approve the Merger Agreement. •“FOR” Proposal No. 2 to approve the ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •“FOR” Proposal No. 3 to approve the ordinary share capital increase regrading the issuance of preferred shares. •“FOR” Proposal No. 4 to approve the reinstatement of the capital band. •“FOR” Proposal No. 5 to approve the conditional share capital for employee and advisory options. •“FOR” Proposal No. 6 to approve the conditional share capital for shareholders’ options. •“FOR” Proposal No. 7 to approve the name change of NLS. •“FOR” Proposal No. 8 to approve the election of the new members to the NLS Board. •“FOR” Proposal No. 9 to approve the election of members of the Compensation, Nomination and Governance Committee. •“FOR” Proposal No. 10 to approve the composition of the new senior management following the Merger. •“FOR” Proposal No. 11.1 to approve the compensation for the members of the NLS Board. •“FOR” Proposal No. 11.2 to approve compensation for the executive officers. •“FOR” Proposal No. 12 to approve the CVR Agreement. •“FOR” Proposal No. 13 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Q.What will happen in the Merger? At the Effective Time, each: •Kadimastem Ordinary Share issued and outstanding immediately prior to the Effective Time will be exchanged for the right to receive a number of newly issued, fully paid and nonassessable NLS Common Shares equal to the Exchange Ratio; •option, restricted share unit, or RSU, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares shall be assumed by NLS and converted into an option, warrant, other award, or right, as applicable, to purchase NLS Common Shares in accordance with the terms of the Merger Agreement; and ix •each NLS Common Share issued and outstanding immediately prior to the Effective Time, and each NLS Common Share acquirable upon the exercise of outstanding warrants of NLS, shall continue to remain outstanding and, in addition, be entitled to a contingent value right, or CVR, pursuant to the terms of the Merger Agreement and the CVR